ClinicalTrials.gg
CompletedNCT03853551Updated Jun 3, 2021Results posted

Osimertinib Study in Indian Patients

A Phase 4 interventional study of Osimertinib in Non Small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca. Completed at 7 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
37th of 90
60 · median 51
Started
2019
with 5 others
Phase 4
4 of 90
2 open now
Registered
44th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 37th largest by enrollment, is one of 6 that started in 2019, is one of 4 in phase 4, and was the 44th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a prospective, single-arm, multicenter, phase-IV study investigating the safety of osimertinib in Indian adult patients.

Read the detailed description

This is a prospective, single-arm, multicenter, phase-IV trial investigating the safety of osimertinib in Indian adult patients with locally advanced or metastatic EGFR-T790M mutation-positive NSCLC.

Prior to data collection, all patients must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements and sponsor policy.

Patients with metastatic EGFR T790M mutation-positive NSCLC, who are eligible to osimertinib treatment as per locally approved prescribing information and ratified by an independent clinical judgment of treating physician will be evaluated for the inclusion into the current phase-IV study based on eligibility criteria. EGFR T790M positivity on plasma or tissue biopsy on PCR-based platform will be considered appropriate test. EGFR T790M must be performed after progressive disease on last line of therapy (on or after EGFR TKI therapy). In order to enroll approximately 60 patients, it is expected that approximately 70 patients will be screened.

03

Conditions studied

  • Non Small Cell Lung Cancer (NSCLC)

Keywords

  • Non small cell lung cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient of either gender and ≥18 years of age
  2. Patients with EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, who have progressed on or after EGFR TKI therapy by an independent clinical judgment of treating physician based on locally approved prescribing information
  3. Each patient must sign an form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. Patient with either the history of to of the study drug or to drugs with a similar chemical structure or class to the study drug.
  2. Pregnant and/or lactating women
  3. Patients participating in any current or future interventional trial will not be enrolled in the current study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Single

    Single arm

    Drug: Osimertinib

Interventions

  • Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.

06

What researchers measure

Primary outcomes

  1. Safety of Osimertinib

    Number of Patients with treatment emergent Adverse Events

    Time frame: 5 months

07

Results

Posted Jun 3, 2021

Participant flow

This was a prospective, open label, single arm, multicentre, India-specific Phase 4 study to investigate the safety of osimertinib 80 mg tablet in Indian adults with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non small cell lung cancer (NSCLC). 60 Indian subjects were enrolled into the study.

Participant flow — Overall Study
MilestoneSingle Arm
Started60
Completed51
Not completed9
Withdrew: Death2
Withdrew: 7 patients discontinued the study because of disease progression.7

Outcome measures

PrimarySafety of Osimertinib

Number of Patients with treatment emergent Adverse Events

Time frame:
5 months
Reported as:
Count of participants · Participants
Safety of Osimertinib
ParticipantsSingle Arm
Safety of Osimertinib60

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm3/60 (5%)7/60 (11.7%)51/60 (85%)
Most frequent serious events
Most frequent serious events
EventSingle Arm
DyspnoeaRespiratory, thoracic and mediastinal disorders2/60
Cardio-respiratory arrestCardiac disorders1/60
CataractEye disorders1/60
Deep Vein ThrombosisVascular disorders1/60
Mouth UlcerationGastrointestinal disorders1/60
DiarrhoeaGastrointestinal disorders1/60
ThrombocytopeniaBlood and lymphatic system disorders1/60
Mucosal inflammationGeneral disorders1/60
Dengue feverInfections and infestations1/60
Disease progressionGeneral disorders1/60
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSingle Arm
FatigueGeneral disorders6/60
Blood creatine phosphokinase increasedInvestigations6/60
DiarrhoeaGastrointestinal disorders5/60
Decreased appetiteGeneral disorders5/60
CoughRespiratory, thoracic and mediastinal disorders5/60
ThrombocytopeniaBlood and lymphatic system disorders4/60
ConstipationGastrointestinal disorders4/60
Mucosal inflammationGeneral disorders4/60
ParonychiaInfections and infestations4/60
Pain in extremityMusculoskeletal and connective tissue disorders4/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Single Arm
Median58 (34 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female31
Male29
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Single Arm
Asian (Only Indian)60
08

Study locations

7 sites
  • Research Site
    Hyderabad, 500034, India
  • Research Site
    Hyderabad, 500096, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Mumbai, 400053, India
  • Research Site
    New Dehli, 110029, India
  • Research Site
    New Delhi, 110085, India
09

References and documents

Publications

  • Malik PS, Noronha V, Dabkara D, Maddu VK, Rajappa S, Limaye S, Batra U. Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India. Indian J Cancer. 2022 Mar;59(Supplement):S1-S10. doi: 10.4103/ijc.ijc_1374_21. PubMed 35343187 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Apr 2020, 11 months.

Results were first posted in Jun 2021, 1 year 1 month after primary completion.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 25, 2019
StartActual
Apr 18, 2019
Primary completionActual
Apr 15, 2020
CompletionActual
Apr 15, 2020
Results first posted
Jun 3, 2021
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03853551
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 25, 2019
Start date
Apr 18, 2019
Primary completion
Apr 15, 2020
Completion
Apr 15, 2020
Results posted
Jun 3, 2021
Last update
Jun 3, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion